Schistosoma mansoni DNA (S. mansoni DNA)

Schistosoma mansoni DNA constitutes the complete genetic blueprint of the trematode parasite responsible for intestinal schistosomiasis, a major neglected tropical disease prevalent in tropical and subtropical regions (World Health Organization, 2023). While most modern anthelmintic drugs target specific proteins or ion channels, the DNA of S. mansoni serves as the primary pharmacological target for the drug oxamniquine. Oxamniquine acts as a prodrug that is enzymatically activated by a parasite-specific sulfotransferase; the resulting reactive metabolite binds covalently to the parasite's DNA, causing irreversible damage and halting the synthesis of DNA, RNA, and proteins (Pica-Mattoccia et al., 2006). This mechanism provides a high degree of selectivity because the activating enzyme is absent in the human host. Beyond its role as a therapeutic target, S. mansoni DNA is a critical biomarker used in molecular diagnostics. Highly sensitive polymerase chain reaction (PCR) assays target specific repetitive sequences within the genome, such as the Sm1-7 tandem repeat, to detect parasite DNA in human clinical samples like stool, urine, or serum (Wichmann et al., 2009). This molecular approach offers a more accurate alternative to traditional microscopy for identifying active infections and monitoring treatment efficacy. Understanding the genomic structure and its susceptibility to chemical modification remains essential for the development of next-generation anthelmintics and the epidemiological surveillance of drug resistance.

Other names

Schistosome DNAS. mansoni genomeSchistosoma mansoni genomic DNASmDNA

DNA alkylation and intercalation leading to the irreversible inhibition of nucleic acid synthesis (Cioli et al., 1995; Pica-Mattoccia et al., 2006).